STOCK TITAN

Vanguard realigns reporting; Vanguard subsidiaries to report GKOS holdings (GKOS)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Glaukos Corp ownership disclosure: The Vanguard Group filed an amendment on 03/13/2026 reporting 0 shares beneficially owned and 0% of the class following an internal realignment and separate reporting by subsidiaries.

The amendment states Vanguard subsidiaries will report beneficial ownership on a "disaggregated basis" in accordance with SEC Release No. 34-39538 (January 12, 1998). The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.

Positive

  • None.

Negative

  • None.

Insights

Amendment shows reallocation of reporting, not a market sale.

The amendment explains that Vanguard underwent an internal realignment and certain subsidiaries will report ownership separately, citing SEC Release No. 34-39538. The filing explicitly lists 0 shares beneficially owned and 0% of the class as of the amendment.

Cash‑flow treatment is not stated; subsequent filings from the listed Vanguard entities may show where holdings are reported. The practical effect is a reclassification of reporting responsibility rather than a disclosed disposition by Vanguard at the parent level.

This is an administrative Schedule 13G/A amendment tied to SEC interpretive release guidance.

The filing cites SEC Release No. 34-39538 and describes disaggregated reporting by subsidiaries that "formerly had, or were deemed to have, beneficial ownership" with Vanguard. The amendment then reports zero ownership for The Vanguard Group itself.

Material investor impact depends on the subsidiary filings; monitoring the separate 13G/A filings from Vanguard entities will clarify beneficial holders and any share movement.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What did the Glaukos (GKOS) Schedule 13G/A amendment report?

The amendment reports that The Vanguard Group beneficially owns 0 shares (0%) of Glaukos Common Stock following an internal realignment and disaggregated reporting by subsidiaries.

Why does Vanguard report zero ownership for GKOS in this filing?

Vanguard states an internal realignment led subsidiaries to report ownership separately "on a disaggregated basis" under SEC Release No. 34-39538; consequently The Vanguard Group reports 0 shares.

Does this filing indicate Vanguard sold Glaukos shares?

No. The filing describes a reporting realignment and separate subsidiary reporting under SEC guidance; it does not state any sales or transfers of shares by The Vanguard Group.

Who signed the Schedule 13G/A amendment for Glaukos?

The amendment is signed by Ashley Grim, Head of Global Fund Administration, with a signature date of 03/26/2026 on the form.

Where will Glaukos ownership previously attributed to Vanguard appear now?

According to the amendment, ownership will be reported by the relevant Vanguard subsidiaries or business divisions separately; investors should check subsequent 13G/A filings from those entities.
Glaukos Corp

NYSE:GKOS

View GKOS Stock Overview

GKOS Rankings

GKOS Latest News

GKOS Latest SEC Filings

GKOS Stock Data

6.37B
55.90M
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
ALISO VIEJO